Nephrocare Health Services Ltd
Nephrocare Health Services Q2 Results 2026 (FY27): Revenue ₹303.4 Cr, PAT ₹33.5 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #14 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
Based on Nephrocare Health Services Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Q2 FY27 EBITDA: ₹67.1 Cr., up from ₹63.9 Cr. in Q2 FY26 (up 5.0%).
From Nephrocare Health Services Ltd's Q2 FY27 earnings-call transcript · updated 3 Nov 2026.
How did Nephrocare Health Services' revenue grow in the September 2026 quarter?
- Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9).
- Q2 FY27 Guests served: 38,814, up 9.6% YoY from 35,425 in Q2 FY26 (Page 9).
- Q2 FY27 Treatments performed: 10,70,105, up 12.0% YoY from 9,55,685 in Q2 FY26 (Page 9).
- Revenue per Treatment (RPT) in Q2 FY27: ₹2,835, up 10.3% YoY from ₹2,571 in Q2 FY26 (Page 9).
What happened to Nephrocare Health Services' margins in Q2 FY27?
See what Nephrocare Health Services Ltd said on profitability & margins — free account, 30 seconds.
What capex is Nephrocare Health Services planning?
- Page 43 shows capital work-in-progress increased slightly from ₹5.5 Cr (Mar-26) to ₹7.1 Cr (Sep-26), suggesting ongoing investments.
- Page 39 reflects a strategy focused on expansion into micro-markets, clusters, and PPPs using an asset-light, capital-efficient model.
- On Page 33, 54 new clinics were added in H1FY27 (15 Captive, 25 PPP, 14 Standalone), mainly through acquisitions and partnerships, indicating capacity scale-up.
2 more points from Nephrocare Health Services Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Nephrocare Health Services raising money or cutting debt?
See what Nephrocare Health Services Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Nephrocare Health Services' order book?
See what Nephrocare Health Services Ltd said on order book & pipeline — free account, 30 seconds.
Nephrocare Health Services Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹282 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Nephrocare Health Services's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q2 FY27)
Q2 FY27 Revenue from Operations: INR 2,554 Mn, up 26.7% YoY (Page 10, 9) . Key investor presentation takeaways from Vijaya Diagnostic Centre Ltd's Q2 FY27 inves
- Shalby (Q2 FY27)
Consolidated Total Revenue for Q2 FY27: ₹3,182 million vs ₹2,899 million in Q2 FY26, up 9.8% YoY (Pages 5, 6, 8, 9) . Key investor presentation takeaways from S
- Metropolis Healt (Q2 FY27)
Q2FY27 revenue from operations: INR 496.8 Cr, up 15.8% YoY (Page 11) . Key investor presentation takeaways from Metropolis Healthcare Ltd's Q2 FY27 investor pre
- Global Health Ltd (Q2 FY27)
Q2 FY2027 revenue from operations: INR 14,690 million, up 33.6% year-on-year (YoY). Key investor presentation takeaways from Global Health Ltd's Q2 FY27 investo
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nephrocare Health Services Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nephrocare Health Services Ltd Q2 FY27 results?
Q2 FY27 Revenue from Operations: ₹303.4 Cr, up 23.5% YoY from ₹245.7 Cr in Q2 FY26 (Page 9). Q2 FY27 EBITDA: ₹67.1 Cr., up from ₹63.9 Cr. in Q2 FY26 (up 5.0%).
What is Nephrocare Health Services Ltd share price analysis?
Nephrocare Health Services Ltd currently shows a neutral. The stock trades at a P/E of 73.8 with a market cap of ₹6,281 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Nephrocare Health Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.